公开(公告)号：US20090239247A1

公开(公告)日：2009-09-24

申请号：US12396879

申请日：2009-03-03

申请人： Adrian L. Harris ,  Peter J. Ratcliffe ,  Dirk Vordermark

发明人： Adrian L. Harris ,  Peter J. Ratcliffe ,  Dirk Vordermark

IPC分类号： G01N33/574 ,  G01N33/53 ,  G01N33/00

CPC分类号： C12Q1/527 ,  G01N33/573 ,  G01N33/574

摘要： The MN/CA IX protein is identified herein as a hypoxia marker. The MN/CA9 gene promoter is characterized, and the location of the HIF-1 binding site within the MN/CA9 promoter is identified. Further, the hypoxia inducibility of the MN/CA9 gene and the uses of such inducibility are disclosed. In one aspect, the invention provides diagnostic/prognostic tools for determining the presence of hypoxia in a tissue in a vertebrate, preferably a human, and for measuring the relative degree of hypoxia in said vertebrate. In another aspect, the invention provides methods using tumor biopsies to predict the radioresistance of a preneoplastic/neoplastic tissue in a vertebrate subject, preferably a human patient, for diseases in which MN/CA IX levels can be used to indicate radiobiologically relevant tumor hypoxia. Such predictive methods can be used as an aid in patient therapy selection.

摘要翻译： 本文将MN / CA IX蛋白质鉴定为缺氧标记。 表征MN / CA9基因启动子，鉴定MN / CA9启动子内HIF-1结合位点的位置。 此外，公开了MN / CA9基因的缺氧诱导能力和这种诱导性的用途。 一方面，本发明提供用于确定脊椎动物，优选人类的组织中缺氧的存在并用于测量所述脊椎动物中的相对缺氧程度的诊断/预后工具。 在另一方面，本发明提供了使用肿瘤活组织检查来预测脊椎动物受试者，优选人类患者中对于其中可以使用MN / CA IX水平来表示放射生物学相关的肿瘤缺氧的疾病的肿瘤前/肿瘤组织的放射抗性的方法。 这种预测方法可用作患者治疗选择的辅助。

公开(公告)号：US20060084123A1

公开(公告)日：2006-04-20

申请号：US11166997

申请日：2005-06-24

申请人： Adrian Harris ,  Peter Ratcliffe ,  Dirk Vordermark

发明人： Adrian Harris ,  Peter Ratcliffe ,  Dirk Vordermark

IPC分类号： G01N33/574

CPC分类号： C12Q1/527 ,  G01N33/573 ,  G01N33/574

摘要： The MN/CA IX protein is identified herein as a hypoxia marker. The MN/CA9 gene promoter is characterized, and the location of the HIF-1 binding site within the MN/CA9 promoter is identified. Further, the hypoxia inducibility of the MN/CA9 gene and the uses of such inducibility are disclosed. In one aspect, the invention provides diagnostic/prognostic tools for determining the presence of hypoxia in a tissue in a vertebrate, preferably a human, and for measuring the relative degree of hypoxia in said vertebrate. In another aspect, the invention provides methods using tumor biopsies to predict the radioresistance of a preneoplastic/neoplastic tissue in a vertebrate subject, preferably a human patient, for diseases in which MN/CA IX levels can be used to indicate radiobiologically relevant tumor hypoxia. Such predictive methods can be used as an aid in patient therapy selection.

摘要翻译： 本文将MN / CA IX蛋白质鉴定为缺氧标记。 表征MN / CA9基因启动子，鉴定MN / CA9启动子内HIF-1结合位点的位置。 此外，公开了MN / CA9基因的缺氧诱导能力和这种诱导性的用途。 一方面，本发明提供用于确定脊椎动物，优选人类的组织中缺氧的存在并用于测量所述脊椎动物中的相对缺氧程度的诊断/预后工具。 在另一方面，本发明提供了使用肿瘤活组织检查来预测脊椎动物受试者，优选人类患者中对于其中可以使用MN / CA IX水平来表示放射生物学相关的肿瘤缺氧的疾病的肿瘤前/肿瘤组织的放射抗性的方法。 这种预测方法可用作患者治疗选择的辅助。